Live tape
Top 8, mentions 7d12,813TSLA3,060 mentions▲ +0.05SPCX2,543 mentions▲ +0.08GOOGL1,703 mentions▲ +0.03META1,528 mentions▲ +0.05NVDA1,002 mentions▲ +0.07QQQ1,001 mentions▲ +0.05CRWV993 mentions▲ +0.04NFLX983 mentions▲ +0.03

Equity · Healthcare

GMAB

NASDAQ

Genmab A/s (GMAB)

$28.71 −1.02% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for GMAB to draw a line in its place.

Track this symbol on TradingView TradingView chart
52-week range $21.08 – $35
Avg volume 642.2K

as of Jul 17, 2026

Genmab A/s (GMAB) reported financials

SEC EDGAR XBRL SEC EDGAR

Genmab A/s reported revenue of $3.7B for the fiscal year ended 31 Dec 2025. Net income over the same period was $963.0M.

Figure Reported Period
Revenue $3.7B 31 Dec 2025 fiscal year
Net income $963.0M 31 Dec 2025 fiscal year
Diluted earnings loss per share $15.37 31 Dec 2025 fiscal year
Total assets $12.9B 31 Dec 2025 at period end
Equity $5.8B 31 Dec 2025 at period end

Genmab A/s (GMAB) institutional holders (13F)

SEC Form 13F SEC EDGAR

7 of the 45 institutional funds we track reported a Genmab A/s position for the quarter ended 30 Jun 2026 — a combined $315.4M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Renaissance Technologies Held (±25%) −20.3% shares 3,517,850 $96.6M
Two Sigma Investments Added +49.9% shares 3,506,843 $96.3M
Citadel Advisors New position 2,475,991 $68.0M
Millennium Management Held (±25%) +14.9% shares 910,604 $25.0M
Marshall Wace Added +5,431.1% shares 829,659 $22.8M
Point72 Asset Management New position 135,647 $3.7M
AQR Capital Management Added +27.4% shares 106,104 $2.9M

Genmab A/s (GMAB) fails-to-deliver

SEC CNS data SEC

On 28 Sep 2026, 3,542 shares of Genmab A/s failed to deliver (about $125K) — the latest of 9 consecutive trading days with recorded fails.

Settlement date Shares failed Notional
28 Sep 2026 3,542 $125K
25 Sep 2026 3,361 $117K
24 Sep 2026 25,237 $877K
23 Sep 2026 9,877 $348K
22 Sep 2026 25,319 $878K
21 Sep 2026 249 $9K
18 Sep 2026 1,479 $51K
17 Sep 2026 677 $23K
16 Sep 2026 1,431 $49K
09 Sep 2026 4,958 $166K

Congressional trades in Genmab A/s (GMAB)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Genmab A/s is a purchase by Josh Gottheimer (house, NJ), dated 16 Jan 2025.

Date Member Type Amount
16 Jan 2025 filed 10 Feb 2025 Josh Gottheimer house · Democrat–NJ Purchase $1K–$15K
16 Dec 2024 filed 14 Jan 2025 Josh Gottheimer house · Democrat–NJ Sale $1K–$15K
19 Jul 2024 filed 15 Aug 2024 Josh Gottheimer house · Democrat–NJ Purchase $1K–$15K
18 Jun 2024 filed 09 Jul 2024 Josh Gottheimer house · Democrat–NJ Sale $1K–$15K
16 Oct 2023 filed 11 Nov 2023 Josh Gottheimer house · Democrat–NJ Purchase $1K–$15K
15 Sep 2023 filed 15 Oct 2023 Josh Gottheimer house · Democrat–NJ Sale $1K–$15K
20 Jul 2023 filed 21 Aug 2023 Josh Gottheimer house · Democrat–NJ Purchase $1K–$15K
19 Jul 2023 filed 21 Aug 2023 Josh Gottheimer house · Democrat–NJ Purchase $1K–$15K

Genmab A/s (GMAB): frequently asked questions

From live data

How many institutions hold Genmab A/s?

7 of the 45 institutional funds we track reported a Genmab A/s position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Genmab A/s had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Genmab A/s is dated 28 Sep 2026, when 3,542 shares failed to deliver.

What exchange is Genmab A/s listed on?

Genmab A/s trades on NASDAQ under the ticker GMAB.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 31 Dec 2025
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures